Frank Rimerman Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Frank Rimerman Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$370K	Sell	1,228 -28	-2%	-$8.45K	0.02%	469
2026 Q1	$416K	Buy	1,256 +6	+0.5%	+$2.04K	0.03%	418
2025 Q4	$497K	Sell	1,250 -1	-0.1%	-$443	0.03%	387
2025 Q3	$570K	Buy	1,251 +24	+2%	+$9.77K	0.04%	341
2025 Q2	$400K	Buy	+1,227	New	+$340K	0.03%	392

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Frank Rimerman Advisors's ALNY Position: Q2 2026 in Review

Frank Rimerman Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 2.2% in Q2 2026, selling an estimated $8.45K and leaving 1,228 shares worth $370K. The position accounts for 0.02% of the portfolio, ranked #469.

Frank Rimerman Advisors first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $570K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Frank Rimerman Advisors held 1,228 shares of Alnylam Pharmaceuticals worth $370K as of Q2 2026.
Frank Rimerman Advisors sold 28 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $8.45K.
Alnylam Pharmaceuticals made up 0.02% of Frank Rimerman Advisors's portfolio in Q2 2026, its #469 holding.
Frank Rimerman Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
Frank Rimerman Advisors's Alnylam Pharmaceuticals position peaked at $570K in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.